How biorix.si registry improved accessibility to targeted therapies - assist. prof. Ziga Rotar
assist. Prof Ziga Rotar
The presentation offers an overview on how rheumatology services are organized in Slovenia, the evolution of accessibility of advanced therapies for patients with inflammatory arthritides emphasizing the positive impact of monitoring effectiveness and safety of these therapies using the online national biorx.si database. Commitment to follow the patients treated with these therapies in biorx.si following the nationally unified recommendations for starting and maintaining advanced therapies proposed by Slovenian rheumatologists reassured the National health insurance to lift virtually all prescription restrictions for these expensive medications. Besides the improved accessibility, the unified recommendations enforced by biorx.si also improved e.g., the use of conventional synthetic disease modifying antirheumatic drugs, reduced use of glucocorticoids, and allowed us to analyse the gathered data for quality control and research.
Assist Prof Ziga Rotar is the current head of the Department of Rheumatology at the University Medical Centre Ljubljana, Ljubljana, Slovenia, and the president of the Slovenian Medical Association – Section of Rheumatology/Slovensko zdravniško društvo – Revmatološka sekcija. He has been involved in real world evidence collection and analyses in patients with inflammatory arthritides treated with targeted therapies since 2006 as the co-author and administrator of the biorx.si registry and collaborator in several international research groups, e.g., CERERRA, TOCERRA, JAK-POT, and EuroSpA.